Pharmaceutical companies AstraZeneca and Merck have unveiled new data that demonstrates the combination of lynparza with abiraterone delays the progression...
Read More...
The post AstraZeneca and Merck record improved survival from combination treatment for mCRPC appeared first on Pharmaceutical Technology.